# A Study to Assess AFM13 in Patients With Hodgkin Lymphoma

> **NCT01221571** · PHASE1 · COMPLETED · sponsor: **Affimed GmbH** · enrollment: 28 (actual)

## Conditions studied

- Hodgkin Lymphoma

## Interventions

- **DRUG:** AFM 13

## Key facts

- **NCT ID:** NCT01221571
- **Lead sponsor:** Affimed GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-10
- **Primary completion:** 2013-05
- **Final completion:** 2013-06
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2013-06-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01221571

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01221571, "A Study to Assess AFM13 in Patients With Hodgkin Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01221571. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*